Author

Thirumaran RK

Director, Genelex Corporation - Cited by 1,863 - Clinical Pharmacogenetics - Clinical Trial Studies and Clinical Lab Operations

Biography

He is affiliated to Genelex Corporation, 3101 Western Ave, Suite 100, Seattle, WA 98121, USA. He is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals.
Title
Cited by
Year
Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms
AL Lindberg, R Kumar, W Goessler, RK Thirumaran, E Gurzau, ...Environmental health perspectives 115 (7), 1081, 2007200
248
2007
Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting.
LV Kalman, JAG Agundez, ML Appell, JL Black, GC Bell, S Boukouvala, ...Clinical Pharmacology and Therapeutics, 2015201
174
2015
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis
S Ugurel, RK Thirumaran, S Bloethner, A Gast, A Sucker, ...PloS one 2 (2), e236, 2007200
162
2007
Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial
LS Elliott, JC Henderson, MB Neradilek, NA Moyer, KC Ashcraft, ...PloS one 12 (2), e0170905, 2017201
143
2017
Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones
M Hu, K Krausz, J Chen, X Ge, J Li, HL Gelboin, FJ GonzalezDrug Metabolism and Disposition 31 (7), 924-931, 2003200
138
2003
Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never and ever smokers
C Ryk, R Kumar, RK Thirumaran, SM HouLung cancer 54 (3), 285-292, 2006200
126
2006
Drug transporters on arachnoid barrier cells contribute to the blood cerebrospinal fluid barrier
K Yasuda, C Cline, P Vogel, M Onciu, S Fatima, BP Sorrentino, ...Drug Metabolism and Disposition 41 (4), 923-931, 2013201
120
2013
Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin
RK Thirumaran, JL Bermejo, P Rudnai, E Gurzau, K Koppova, W Goessler, ...Carcinogenesis 27 (8), 1676-1681, 2006200
100
2006
Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations
D Scherer, E Nagore, JL Bermejo, A Figl, R Botella‐Estrada, ...International journal of cancer 125 (8), 1868-1875, 2009200
83
2009
Determination of allele frequency in pooled DNA: comparison of three PCR based methods.
S Wilkening, K Hemminki, RK Thirumaran, JL Bermejo, S Bonn, A Försti, ...Biotechniques 39 (6), 853-858, 2005200
75
2005
MTHFR genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia
RK Thirumaran, A Gast, T Flohr, B Burwinkel, C Bartram, K Hemminki, ...Blood 106 (7), 2590-2591, 2005200
62
2005
Intestinal CYP3A4 and Midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.
SEG Thirumaran RK, Lamba JK, Kim RB, Urquhart BLBiochemical Pharmacology 1 (84 (1)), 104-12, 201258201
58
2012
Cytochrome P–450 gene and drug interaction analysis in patients referred for pharmacogenetic testing
BT Hocum, JR White Jr, JW Heck, RK Thirumaran, N Moyer, R Newman, ...American Journal of Health-System Pharmacy 73 (2), 61-67, 2016201
53
2016
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
KC Brown, MC Hosseinipour, JM Hoskins, RK Thirumaran, HC Tien, ...Pharmacogenomics, 1-9, 2011201
48
2011
Multisite phosphorylation of human liver cytochrome P450 3A4 enhances its gp78-and CHIP-mediated ubiquitination: A pivotal role of its S478 residue in the gp78-catalyzed reaction.
Y Wang, S Guan, P Acharya, RK Thirumaran, Y Liu, R Brandman, ...Molecular & cellular proteomics: MCP, 2011201
37
2011
Single nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma
A Figl, D Scherer, E Nagore, JL Bermejo, R Estrada, A Gast, ...Mutation Research/Genetic Toxicology and Environmental Mutagenesis 702 (1), 8-16, 2010201
34
2010
Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients
A Figl, D Scherer, E Nagore, JL Bermejo, E Dickes, RK Thirumaran, ...Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 661 (1 …, 2009200
33
2009
The influence of sex, ethnicity, and CYP2B6 genotype on Bupropion metabolism as an index of hepatic CYP2B6 activity in humans
K Ilic, RL Hawke, RK Thirumaran, EG Schuetz, JH Hull, ADM Kashuba, ...Drug Metabolism and Disposition 41 (3), 575-581, 2013201
33
2013
Genetic variation in aldo-keto reductase 1D1 affects the expression and activity of multiple cytochrome P450s
AS Chaudhry, RK Thirumaran, K Yasuda, X Yang, Y Fan, SC Strom, ...Drug Metabolism and Disposition 41 (8), 1538-1547, 2013201
28
2013
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
MA Perera, RK Thirumaran, NJ Cox, S Hanauer, S Das, C Brimer-Cline, ...The pharmacogenomics journal 9 (1), 49-60, 2009200
26
2009

Referred From: https://scholar.google.com/citations?user=1Sowb6AAAAAJ&hl=en

Cited by
Citations 1863
h-index 21
i10-index 25
Recommended Journals
Open Access Journals